Dupuytren's disease in diabetes mellitus.

Dupuytren's disease (DD) was demonstrated in 169 of 959 diabetics (17.6%) and in 9 of 1,396 non-diabetic patients (0.64%). One hundred and seventy-nine of the 185 patients with DD had overt or latent diabetes mellitus (96.7%). The relative frequency of DD increased with age, the conditions was seldom found under the age of 40. DD should be regarded as a non-hyperglycemic manifestation of diabetes mellitus and its presence in a patient should prompt the investigation of glucose metabolism.

Phenytoin bioavailability assessed by steady state serum concentrations.

The effect of a change in bioavailability of phenytoin sodium formulations on steady state serum concentrations was assessed in two groups of neurosurgical patients (n = 20 and 12). One group was studied in 1980 while on the old formulation, the other in 1983 while on the new formulation. Data were also obtained from routine therapeutic-level monitorings in 85 ambulatory patients receiving the new formulation during 1984. Phenytoin levels on the 400-mg/day dose were 10.9 +/- 4.1 (SD) and 16.1 +/- 5.6 micrograms/ml on the old and new formulations, respectively (P less than 0.01) in the neurosurgical patients. Routinely monitored levels on the 300-mg/day dose were 6.9 +/- 4.9 and 12.1 +/- 6.8 micrograms/ml, respectively (P less than 0.01). The maximum elimination rate of phenytoin, estimated from steady state dose-concentration pairs, was significantly higher on the old formulation (9.5 +/- 2.8 vs. 7.2 +/- 1.1 mg/kg per day, P less than 0.025) even though there was no difference in the estimates of the Michaelis-Menten constant. The proportion of subtherapeutic levels on ostensibly equal doses fell from 85 to 45% on 300 mg/day of the two formulations (P less than 0.01), and to 28% on 400 mg/day of the new formulation. Steady state concentrations may be used to assess increased bioavailability of drugs with capacity-limited metabolism, such as phenytoin.